Artist's Conk

Metadata

Regulatory Status

China

• Traditional use: Ganoderma applanatum has been used in traditional Chinese medicine as a secondary Ganoderma species, sometimes under the general name “Lingzhi” alongside the more valued G. lucidum. In some regional practices, particularly where G. lucidum was scarce, G. applanatum served as a substitute. Classical texts occasionally reference flat shelf-forming Ganoderma species without clear species delimitation.
• Pharmacopoeia status: Not listed as a specific entry in the Chinese Pharmacopoeia (2020 edition). The Pharmacopoeia Ganoderma entry covers G. lucidum and G. sinense but does not include G. applanatum.

Japan

• Recognition: Known as Kofukitake in Japanese. Used in folk medicine but not as a major medicinal mushroom species in Kampo practice. No pharmaceutical approval.

European Union

• Novel Food: Not assessed under Regulation (EU) 2015/2283. No EMA/HMPC monograph or assessment report.
• Folk use: G. applanatum has a history of folk medicinal use in Central and Eastern Europe, where bracket fungi were traditionally prepared as teas and tinctures for general health support, wound care, and as hemostatic agents.

United States

• Dietary supplement: Available as a dietary supplement under DSHEA, though market presence is minimal compared to G. lucidum (Reishi). Often sold in “Ganoderma complex” blends containing multiple species.
• FDA GRAS: No GRAS determination. No therapeutic claims evaluated.

Indigenous and Folk Medicine Traditions

G. applanatum has been used across diverse folk medicine traditions worldwide, reflecting its cosmopolitan distribution:

• North American indigenous use: Some First Nations and Native American peoples used G. applanatum as “Bear Bread,” preparing teas from the hard fruiting body for general tonic purposes, respiratory complaints, and wound care.
• European folk medicine: Used in Slavic and Scandinavian folk traditions as a tea for digestive complaints and general strengthening.
• Asian folk medicine: Regional use in Chinese, Japanese, and Korean folk traditions, typically as a lower-cost alternative to G. lucidum.

Conditions & Indications

No Conditions with Human Clinical Trial Evidence

There are no published randomized, double-blind, placebo-controlled clinical trials of Ganoderma applanatum in humans for any indication. All conditions listed below are supported only by preclinical data (in vitro and animal studies) or traditional/folk use. This is the central limitation of the G. applanatum evidence base.

Preclinical Evidence Only

Anti-inflammatory Activity

Applanoxidic acids and other lanostane-type triterpenoids from G. applanatum demonstrate anti-inflammatory activity in preclinical models. Applanoxidic acid A inhibits cyclooxygenase (COX) activity and suppresses pro-inflammatory mediator production in LPS-stimulated macrophages. Chairul et al. (1994) isolated and characterized applanoxidic acids from G. applanatum fruiting bodies and demonstrated inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in a mouse ear edema model. Multiple applanoxidic acid variants (A through G) have been characterized, each with somewhat distinct anti-inflammatory potency.

Antioxidant Activity

Ethanol and water extracts of G. applanatum demonstrate radical-scavenging activity in standard in vitro assays (DPPH, ABTS, FRAP), attributed to polyphenolic compounds, ergosterol peroxide, and triterpenoid constituents. Kozarski et al. (2011) reported significant antioxidant activity in polysaccharide extracts from G. applanatum, comparable to ascorbic acid standards in some assays. As with all in vitro antioxidant data, translation to in vivo human effects remains unvalidated.

Cytotoxic and Antitumor Activity

Triterpenoids and polysaccharides from G. applanatum demonstrate antiproliferative effects against multiple cancer cell lines in vitro. Ergosterol peroxide, ganodermanontriol, and applanoxidic acids show cytotoxicity against HeLa (cervical), HepG2 (hepatocellular), MCF-7 (breast), and A549 (lung) cancer cell lines. Mechanisms include apoptosis induction through caspase activation and cell cycle arrest. Jeong et al. (2008) reported that G. applanatum polysaccharide fractions activated macrophages and enhanced antitumor immune responses in a murine sarcoma model. However, no human tumor studies exist.

Immune Modulation

Water-soluble polysaccharides from G. applanatum activate macrophages and dendritic cells through pattern recognition receptors (Dectin-1, TLR-2), stimulating pro-inflammatory cytokine production and enhancing phagocytic activity. Usui et al. (1983) were among the first to characterize the immunostimulatory beta-glucans from G. applanatum, demonstrating antitumor activity of the polysaccharide fraction against sarcoma 180 in mice. The polysaccharide immunomodulatory profile is qualitatively similar to that of G. lucidum, though quantitative potency comparisons are sparse.

Antimicrobial Activity

Extracts of G. applanatum show broad-spectrum antimicrobial activity in vitro against both Gram-positive and Gram-negative bacteria, as well as some fungi. Triterpenoids and ethanol-soluble fractions demonstrate antibacterial activity against Staphylococcus aureus, Bacillus subtilis, and Escherichia coli in disc diffusion assays. Antifungal activity has been reported against Candida albicans. Clinical significance of these in vitro findings is unknown.

Traditional Uses (Folk Medicine)

• General tonic: Decoction of dried fruiting body consumed as a strengthening tea, particularly during convalescence
• Respiratory complaints: Folk use for cough, bronchitis, and asthma across Asian and North American traditions
• Wound care: External application as a styptic (hemostatic) agent in some indigenous traditions
• Digestive complaints: Tea preparation for gastritis, indigestion, and intestinal inflammation in European folk use
• Adaptogenic: Used as a vitality and stress-resistance tonic, analogous to reishi but with less formal codification in classical medical texts

Mechanism of Action

1. Applanoxidic Acid Triterpenoid Bioactivity

Applanoxidic acids are a class of lanostane-type triterpenoids unique to Ganoderma applanatum. At least seven structural variants (applanoxidic acids A through G) have been isolated and characterized. Their principal mechanisms include:

• Anti-inflammatory activity: Inhibition of COX-1 and COX-2 enzymatic activity, suppression of TPA-induced inflammation, and reduction of pro-inflammatory cytokine production in activated macrophages. Chairul et al. (1994) demonstrated inhibition of TPA-induced ear edema in mice.
• Cytotoxic activity: Induction of apoptosis in cancer cell lines through mechanisms that remain incompletely characterized but appear to involve mitochondrial membrane depolarization and caspase activation.
• Structural distinction from ganoderic acids: While both applanoxidic acids and ganoderic acids belong to the lanostane triterpenoid class, they differ in their oxygenation patterns, stereochemistry, and ring modifications, resulting in distinct pharmacological profiles. G. applanatum contains both applanoxidic acids (unique) and some ganoderic acids (shared with G. lucidum), but in different proportions and with different structural variants than those found in reishi.

2. Beta-Glucan Polysaccharide Immune Activation

Like other Ganoderma species, G. applanatum produces water-soluble polysaccharides, primarily beta-1,3-D-glucans with 1,6-branching, that activate innate immune cells through pattern recognition receptors. Usui et al. (1983) characterized the immunostimulatory polysaccharide fraction and demonstrated antitumor activity against sarcoma 180 in mice, confirming that the beta-glucan immune-activation pathway common to medicinal mushrooms is operative in this species. The polysaccharides activate macrophages through Dectin-1 and TLR-2 signaling, driving NF-kB-mediated cytokine production (TNF-alpha, IL-6, IL-12), enhanced phagocytic activity, and NK cell activation.

3. Ergosterol Peroxide Bioactivity

Ergosterol peroxide (5-alpha,8-alpha-epidioxyergosta-6,22-dien-3-beta-ol) is present in G. applanatum at pharmacologically relevant concentrations. This compound demonstrates:

• Cytotoxic activity: Apoptosis induction in multiple cancer cell lines through activation of both intrinsic and extrinsic apoptosis pathways.
• Anti-inflammatory: Inhibition of LPS-induced NF-kB activation and downstream pro-inflammatory gene expression.
• Immunomodulatory: Modulation of macrophage activation and cytokine production.
• Ergosterol peroxide is shared across many medicinal mushroom species and is not unique to G. applanatum, but it contributes to the overall bioactive profile.

4. Polyphenolic Antioxidant Activity

G. applanatum contains polyphenolic compounds with radical-scavenging and metal-chelating properties. These compounds contribute to the antioxidant activity observed in vitro and may provide cytoprotective effects through Nrf2-mediated induction of phase II detoxification enzymes, though this pathway has not been specifically validated for G. applanatum extracts.

Key Pharmacological Note

G. applanatum shares the fundamental polysaccharide + triterpenoid dual pharmacological architecture with G. lucidum (Reishi), but with a distinct triterpenoid fingerprint. The applanoxidic acids are unique to G. applanatum and represent an untapped source of bioactive lanostane triterpenoids. However, the total triterpenoid content of G. applanatum fruiting body is generally lower than that of G. lucidum, and the polysaccharide fractions, while qualitatively similar, have not been as extensively characterized for immunological potency. As with other hard, woody bracket fungi, hot-water extraction releases polysaccharides while ethanol extraction captures triterpenoids and ergosterol derivatives. Dual extraction provides the broadest spectrum.

Clinical Evidence Summary

Human Clinical Trials

There are no published randomized, double-blind, placebo-controlled clinical trials of Ganoderma applanatum in humans for any indication. This statement, current as of February 2026, is the most important fact in this monograph. The species has been almost entirely overlooked in clinical research in favor of its far more famous congener G. lucidum (Reishi), which has a Cochrane systematic review of RCTs in cancer adjunctive therapy.

Preclinical Evidence Summary

Evidence Comparison with Ganoderma lucidum (Reishi)

The evidence gap between G. applanatum and G. lucidum is stark. Reishi has two Cochrane systematic reviews (one for cancer adjunctive therapy, one for cardiovascular risk factors), multiple RCTs, and centuries of formally codified traditional medical use across Chinese, Japanese, and Korean pharmacopoeias. G. applanatum has no clinical trials, no systematic reviews, and only scattered folk use without formal pharmacopoeia recognition. Despite sharing the same genus and overlapping bioactive compound classes, the clinical evidence base is incomparable. This reflects a research prioritization gap rather than necessarily a pharmacological inferiority — G. applanatum’s unique applanoxidic acid triterpenoids have simply not been investigated in clinical settings.

The “Reishi Shadow” Problem

G. applanatum suffers from what might be called a “Reishi shadow” effect: the overwhelming research and commercial focus on G. lucidum has left G. applanatum and other Ganoderma species underinvestigated. This is compounded by historical misidentification, as G. applanatum has sometimes been collected and sold as “wild reishi” or included in Ganoderma blends without species-level authentication. The two species are readily distinguishable macroscopically — G. lucidum has a lacquered (varnished) cap surface, while G. applanatum has a dull, matte surface — but dried, powdered, or extracted material cannot be visually differentiated without molecular analysis.

Safety Profile

General Assessment

Ganoderma applanatum has been consumed as a tea or decoction in folk medicine traditions across multiple continents without widespread reports of acute toxicity. The hard, woody fruiting body is consumed exclusively in extracted form (decoction, tincture, or powder), not as a whole food. Systematic safety data from controlled human studies is entirely absent. General safety is inferred from traditional use history and from the safety profile of the closely related G. lucidum, though cross-species safety extrapolation has inherent limitations.

Contraindications

• Autoimmune conditions: Immunostimulatory beta-glucan polysaccharides could theoretically exacerbate autoimmune disease activity, as with other medicinal mushrooms containing immunomodulatory beta-glucans.
• Pre-surgical: Discontinue at least 2 weeks before elective surgery as a precautionary measure. Some Ganoderma triterpenoids demonstrate antiplatelet activity in vitro.
• Pregnancy and lactation: No human safety data. Avoid during pregnancy and lactation.

Drug Interactions

No drug interactions have been documented for G. applanatum specifically in human studies or case reports. Theoretical considerations, inferred partly from the pharmacology of the related G. lucidum, include:

• Anticoagulants/antiplatelets: Some Ganoderma triterpenoids inhibit platelet aggregation in vitro. Clinical significance for G. applanatum specifically is unknown.
• Immunosuppressants: Beta-glucan immunostimulation could theoretically counteract immunosuppressive therapy.
• Antihypertensives: Theoretical additive hypotensive effects based on Ganoderma genus pharmacology, though specific data for G. applanatum is absent.
• CYP450 substrates: No specific data for G. applanatum. Caution warranted by analogy with G. lucidum ganoderic acid CYP inhibitory potential, though the different triterpenoid profile may result in a different interaction profile.

Side Effects

• Common (at traditional tea doses): Generally well-tolerated based on folk use history. Bitter taste of the decoction is notable.
• Uncommon: Mild gastrointestinal discomfort (nausea, bloating) reported anecdotally.
• Serious: No serious adverse events reported in the published literature for G. applanatum specifically.

Toxicology

• No formal toxicology studies specific to G. applanatum have been identified in the published literature.
• General safety is inferred from traditional use and from the Ganoderma genus safety profile. The absence of specific toxicological data is itself a safety concern that limits confident dosage recommendations.
• The fruiting body may accumulate heavy metals from contaminated substrates, as with other bracket fungi; sourcing from clean environments is important.

Pregnancy and Lactation

• Category: Unknown — insufficient data. No controlled human studies. Avoid during pregnancy and lactation until safety is established.

Clinical Dosage

Important Caveat

Because no human clinical trials exist for Ganoderma applanatum, there are no evidence-based dosage recommendations. All dosage information below is extrapolated from folk use practices and by analogy with the better-studied G. lucidum, adjusted for the differences in triterpenoid content. These should be considered rough guidelines, not validated therapeutic doses.

Traditional Decoction

• Method: Dried fruiting body sliced or broken into pieces and simmered in water for 1-3 hours
• Dose: 3-10 g of dried fruiting body per day, prepared as decoction
• Note: The extremely hard, woody texture of the perennial basidiocarp requires prolonged simmering; the resulting decoction has a distinctly bitter taste from triterpenoid extraction

Hot-Water Extract

• Standard dose: 1-3 g/day of concentrated hot-water extract powder
• Extraction: Hot-water extraction at 80-100 degrees C releases beta-glucan polysaccharides from the chitin matrix
• Note: Hot water alone does not efficiently extract applanoxidic acids and other triterpenoids

Dual Extract (Water + Ethanol)

• Standard dose: 1-3 mL of dual-extract tincture, 1-3 times daily
• Captures both water-soluble polysaccharides and alcohol-soluble applanoxidic acids, ganoderic acids, and ergosterol peroxide
• Recommended for the broadest bioactive spectrum

Dried Powder (Capsule)

• Standard dose: 1-3 g/day in divided doses
• Note: Unextracted powder has significantly lower bioavailability than extracted preparations due to the extremely dense, woody chitin matrix of the perennial fruiting body

Sourcing Considerations

G. applanatum is one of the most common bracket fungi worldwide, found on dead and dying hardwood trees in temperate and subtropical forests across all inhabited continents. Wild-harvested material is readily available but should be sourced from environments free of heavy metal contamination (avoid specimens from roadsides, industrial areas, or contaminated soils). Species identification should be confirmed, as G. applanatum can be confused with other large bracket fungi. The white pore surface that bruises brown on contact is the most reliable field identification feature.

Sources

• Chairul, Tokuyama T, Hayashi Y, et al. Applanoxidic acids A, B, C, and D: biologically active triterpenoids from Ganoderma applanatum. Phytochemistry. 1994;35(5):1305-1308
• Usui T, Iwasaki Y, Hayashi K, et al. Antitumor activity of water-soluble beta-D-glucan elaborated by Ganoderma applanatum. Agric Biol Chem. 1983;47(6):1289-1293
• Kozarski M, Klaus A, Niksic M, et al. Antioxidative and immunomodulating activities of polysaccharide extracts of the medicinal mushrooms Agaricus bisporus, Agaricus brasiliensis, Ganoderma lucidum and Phellinus linteus. Food Chem. 2011;129(4):1667-1675
• Jeong YT, Yang BK, Jeong SC, Kim SM, Song CH. Ganoderma applanatum: a promising mushroom for antitumor and immunomodulating activity. Phytother Res. 2008;22(5):614-619
• Smania EF, Delle Monache F, Smania A Jr, Yunes RA, Cuneo RS. Antifungal activity of sterols and triterpenes isolated from Ganoderma annulare. Fitoterapia. 2003;74(4):375-377
• Ryvarden L, Gilbertson RL. European Polypores. Part 1. Synopsis Fungorum 6. Oslo: Fungiflora; 1993
• Paterson RR. Ganoderma — a therapeutic fungal biofactory. Phytochemistry. 2006;67(18):1985-2001
• Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007;13:265-301
• Ma HT, Hsieh JF, Chen ST. Anti-diabetic effects of Ganoderma lucidum. Phytochemistry. 2015;114:109-113
• Hapuarachchi KK, Wen TC, Deng CY, et al. Mycosphere essays 1. Taxonomic confusion in the Ganoderma lucidum species complex. Mycosphere. 2015;6(5):542-559
• Richter C, Wittstein K, Kirk PM, Stadler M. An updated summary of new names of important medical fungi. Mycol Prog. 2015;14:34
• Zhou LW, Cao Y, Wu SH, et al. Global diversity of the Ganoderma lucidum complex (Ganodermataceae, Polyporales) inferred from morphology and multilocus phylogeny. Phytochemistry. 2015;114:7-15
• Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 9
• Memorial Sloan Kettering Cancer Center. Reishi Mushroom monograph. mskcc.org (accessed February 2026)

Connections

• Compare with Reishi (Ganoderma lucidum) — the dominant species in the Ganoderma genus for medicinal use; both share the polysaccharide + triterpenoid dual pharmacological architecture and belong to the same family, but their triterpenoid profiles are distinct: G. lucidum is defined by ganoderic acids (over 150 characterized), while G. applanatum is defined by applanoxidic acids (unique to this species); reishi has two Cochrane systematic reviews and formal pharmacopoeia recognition that G. applanatum entirely lacks
• Compare with Chaga (Inonotus obliquus) — another common bracket fungus with extensive folk use history and preclinical data but no human clinical trials; both represent cases where traditional reputation and ecological abundance have not translated into clinical investigation; however, their bioactive profiles are fundamentally different (G. applanatum emphasizes lanostane triterpenoids, chaga emphasizes betulinic acid and melanin)
• Compare with Fomitopsis betulina (Birch Polypore) — a fellow perennial bracket fungus with European folk medicine credentials and preclinical evidence; both are common, widely distributed wood-decay fungi that have been used medicinally but remain clinically unvalidated
• The “Reishi shadow” problem — G. applanatum’s minimal research profile is partly a consequence of the overwhelming scientific and commercial focus on G. lucidum; the unique applanoxidic acid triterpenoids represent an underexplored pharmacological resource that merits dedicated investigation independent of the reishi research paradigm
• G. applanatum is one of the most commonly encountered bracket fungi worldwide, fruiting on dead hardwoods in forests, parks, and urban environments; its ecological abundance and ease of identification make it an accessible species, but this familiarity may paradoxically contribute to its being overlooked as a medicinal resource
• Wild specimens of G. applanatum are sometimes misidentified and sold as “wild reishi” or mixed into Ganoderma blend products; molecular species authentication is important for both research and commercial quality assurance